GlassScriptPhysician profile
Harinder Gill
NPI 1285608000
$9,250.05
in general payments reported to CMS, 2019-2025
32 companies · $2,094 in 2025
The $2,094 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $588 · 2021: $1,454 · 2022: $1,021 · 2023: $1,331 · 2024: $1,695 · 2025: $2,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,806 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,805.74 |
| Education | $313.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,572.78 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,571.92 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,186.05 | 2021-2025 | Dupixent |
| Genzyme Corporation | $760.40 | 2019-2025 | |
| Amgen INC. | $617.28 | 2021-2025 | Tezspire |
| Medtronic, INC. | $562.42 | 2021 | |
| Mylan Specialty L.P. | $223.43 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.23 | 2019-2025 | Jascayd |
| Stryker Corporation | $202.86 | 2025 | Mako |
| Sanofi-Aventis U.S. LLC | $199.90 | 2024 | |
| Neurocrine Biosciences, INC. | $151.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $144.27 | 2019-2024 | |
| Electromed, INC. | $88.24 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $84.06 | 2025 | Ohtuvayre |
| Pfizer INC. | $78.07 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $72.07 | 2022-2023 | Hillrom - Visivest Airway Clearance System |
| Insmed, INC. | $61.51 | 2021-2025 | Arikayce |
| Grifols USA, LLC | $50.10 | 2020-2023 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $46.68 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $46.15 | 2019-2021 | |
| Viatris Specialty LLC | $44.70 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $40.96 | 2021-2022 | |
| Genentech USA, INC. | $35.93 | 2021-2022 | |
| Advanced Respiratory, INC | $35.64 | 2021 | |
| Abbott Laboratories | $28.63 | 2023 | Freestyle Libre 2 |
| Ani Pharmaceuticals, INC. | $22.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.44 | 2024 | Glassia |
| Novo Nordisk INC | $21.08 | 2021 | |
| Philips North America LLC | $20.67 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.48 | 2019 | |
| Allergan, INC. | $15.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harinder Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.